Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images)

No­var­tis scut­tles tri­al for pro­gram laud­ed by Vas Narasimhan as emerg­ing trans­plant drug star

A pro­gram tout­ed by No­var­tis CEO Vas Narasimhan as a near-slam dunk has flopped a Phase IIb study, lead­ing the Swiss bio­phar­ma to dis­con­tin­ue the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.